GleamWall
中文EN

VBIO Valion Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787740 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-49.6%
TTM net income YoY-16.9%
TTM EPS YoY—
Revenue 3-yr CAGR-35.8%
Net income 3-yr CAGR—

Margins

Gross margin-58.1%
Operating margin-1,210.8%
Net margin-1,557.3%
FCF margin-1,263.5%
EBITDA margin-1,210.4%

Returns

ROE-240.3%
ROA-156.0%
ROIC (approx.)-1,514.1%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312026-03-302026-03-302025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————$146,000$86,000$70,000$180,000
Cost of revenue————$291,000$32,000$20,000$419,000
Gross profit————-$145,000$54,000$50,000-$239,000
R&D expense$2.70M$1.85M$1.85M$1.28M$858,000$655,000$335,000$333,000
SG&A expense$3.72M$3.78M$3.78M$1.75M$1.06M$1.02M$1.04M$730,000
Operating income-$6.42M-$5.63M—-$1.98M-$2.48M-$1.68M-$1.38M-$298,000
Interest expense$691,000$648,000$648,000——$0$0—
Net income-$7.10M-$6.20M—-$2.85M-$2.60M-$1.93M-$1.50M-$1.48M
EBITDA-$6.07M-$5.63M—-$1.97M-$2.48M-$1.68M-$1.38M-$298,000
EPS (basic)-2.17-2.23——-1.97-2.19-2.52—
EPS (diluted)—————-2.19-2.52—
Weighted avg. shares (diluted)—————881,294596,368—
Banking
Net interest income—————$3,000$4,000—
Balance sheet
Cash & equivalents$2.11M$7.21M—$12.64M$3.45M$1.18M$669,000$2.00M
Receivables————$19,000$13,000$13,000$69,000
Inventory$750,000$750,000—$0$4,000$283,000$306,000$319,000
Current assets$3.38M$8.65M—$13.01M$3.74M$1.84M$1.26M$2.64M
PP&E, net$12.34M$12.64M—$12.64M$12,000$120,000$118,000$2,000
Goodwill$3.46M$3.46M—$3.46M———$0
Intangibles$2.24M$2.24M—$2.24M$2.24M——$0
Total assets$32.47M$38.22M—$31.61M$6.23M$4.51M$3.78M$2.81M
Current liabilities$3.05M$2.62M—$646,000$638,000$821,000$741,000$272,000
Total liabilities$20.59M$19.67M—$7.44M$638,000$821,000$741,000$272,000
Shareholders' equity$4.25M$11.06M—$16.80M$3.41M$3.69M$3.04M$2.54M
Shares outstanding4.15M2.88M—2.53M1.66M965,899705,641556,902
Cash flow statement
Operating cash flow-$5.28M-$5.01M—-$2.29M-$2.00M-$1.83M-$889,000-$1.36M
Capital expenditure$57,000$7,000—$25,000$10,000$3,000$0$0
Free cash flow-$5.34M-$5.02M—-$2.31M-$2.01M-$1.83M-$889,000-$1.36M
Investing cash flow-$57,000-$7,000—-$149,000-$10,000-$20,000-$526,000$0
Financing cash flow$231,000-$44,000—$11.63M$4.27M$2.36M$82,000$1.18M
Depreciation & amortization$358,000$4,000—$3,000$0$1,000$1,000$0
Stock-based compensation$133,000$208,000—$149,000$138,000$177,000$100,000$63,000

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.